Physician profile
Michael Gaugler
NPI 1407818180
$2,746.01
in general payments reported to CMS, 2019-2025
24 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $289 · 2021: $401 · 2022: $548 · 2023: $354 · 2024: $539 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $554.99 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $403.81 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $389.74 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.56 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $171.09 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $154.99 | 2024-2025 | Zenpep, Vowst |
| Intercept Pharmaceuticals, INC. | $111.08 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $110.89 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $65.61 | 2020-2024 | Linzess |
| Allergan, INC. | $61.82 | 2019 | |
| Celgene Corporation | $58.96 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $58.17 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $53.49 | 2019-2024 | Suflave |
| Regeneron Healthcare Solutions, INC. | $42.39 | 2022-2024 | Dupixent |
| Daiichi Sankyo INC. | $41.63 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $32.29 | 2019-2022 | |
| Pfizer INC. | $28.10 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $26.06 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $23.12 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $18.95 | 2023 | |
| Genzyme Corporation | $15.82 | 2023 | |
| Lilly USA, LLC | $15.37 | 2025 | Omvoh |
| Amag Pharmaceuticals, INC. | $14.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gaugler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.